Gemcitabine‐induced MAPK signalling is a key cause of chemotherapy resistance, and inhibiting MAPK signalling pathways with Erlotinib prolongs pancreatic cancer patient survival.30 Thus, targeting dCK to inhibit the resultant ERK1/2 activation and NRF2/ARE axis might provide novel treatment targets for metastatic pancreatic cancer. This evidence concerns the gene NFE2L2 and familial pancreatic carcinoma.